On December 2, 2020, American bio-manufacturing startup Dimension Inx announced that it has received a seed round of US$3.175 million (approximately 20.8 million yuan). This round of investment was led by leading early-stage venture capital firm KdT Ventures.They plan to use the funds to accelerate the use of tissue repair and regeneration3D printingCommercial development of therapeutic implants and application for US Food and Drug Administration (FDA) approval.
Dimension Inx was established in 2017. As a spin-off company of Northwestern University in the United States, Dimension Inx has developed a biological manufacturing process, and has a patented material and manufacturing platform that can be used for the repair and regeneration of human tissue3D printingImplants. This technology overcomes existing challenges in the fields of biomaterials and rapid prototyping manufacturing, enabling important components and microstructural features in surgical implants to be realized and promoting healing.
In order to transform their research from the workbench to the clinic, Dimension Inx cooperated with well-known universities and hospitals, such as Emory University, Philadelphia Children’s Hospital, Carnegie Mellon University, Nanyang Technological University, etc.
After obtaining this round of seed financing, Dimension Inx will be able to create the first therapeutic implant for facial reconstruction of post-traumatic patients, as well as those tooth deformities caused by congenital defects or aging. The company expects to complete the FDA’s 510(k) preclinical study next summer, which will prove that the device is safe and effective and can be marketed. Other participants in this round of investment also include venture capital firm Better Ventures and Revolution Ventures’ investment fund Rise of the Rest Seed Fund. This is Dimension Inx’s second round of financing. The first round of financing was completed in 2019 and successfully raised $350,000 from the investment company Digital Industrialist.
Phil Grayeski, head of KdT Ventures, said: “Dimension Inx is3D bioprintingThe materials experts of, their commercialization and regulatory approval methods are pragmatic. Each new product demonstrates the capabilities of their materials and provides information for the development and verification of the platform in the application of regenerative medicine. We believe that the world of bioprinting will be built on the architecture that Dimension Inx is creating, and we are very happy to be able to support this company. “
When the original technology of Dimension Inx was derived from Ramille Shah’s laboratory at Northwestern University, the associate professor of materials science and the co-founder of Dimension Inx were trying to promote the development of the laboratory.3D printingTransformation and commercialization of material technology. Shah is3D printingA well-known leader in the field of materials development, he has been working on new methods from printing of ovarian organs and musculoskeletal tissue to printing metal, Mars and moon dust.
As the Chief Scientific Officer (CSO) of Dimension Inx, Shah has been guiding the overall strategy of this start-up company, leading everyone to strive for FDA approval for basic products. So far, the company claims that the 3D-Painting biomaterial design and manufacturing system provides the versatility, manufacturability and affordability required for regenerative tissue engineering medical products, and can fundamentally change the way to treat human diseases and debilitating.
The proprietary 3D-Painting technology can achieve a high load of biologically active ingredients, quickly print and dry at room temperature, and eliminate processing technologies such as cross-linking and sintering.This production and3D printingThe high-particle content 3D ink method is ideal for surgical implants that promote healing and tissue regeneration, and accelerate the manufacturing speed to support the commercialization of new medical products.
Obtaining the latest seed funding makes Dimension Inx one step closer to transforming bio-manufacturing technology into clinical treatment methods, which can greatly improve medical standards, solve the problem of shortage of donor tissues and organs, and verify years of research. In order to provide regenerative medical products to patients in need, the company continues to move towards the clinical stage, cooperating with clinicians, surgeons and forward-looking medical product companies to provide patients with new medical solutions.
Caralynn Nowinski Collens, co-founder and CEO of Dimension Inx, said of the transaction: “We are very fortunate to work with investors. They support our vision and appreciate our pragmatic approach to the market. Understand the deep science involved in achieving our goals. We look forward to promoting the development of science and expanding our strategic partnership to solve a wider range of surgical applications.”
(Editor in charge: admin)
0 Comments for “Dimension Inx receives USD 3.2 million in seed investment to develop 3D printed tissue implants”